Physician profile
Devon S Mckenzie
NPI 1497152888
$21,760.17
in general payments reported to CMS, 2019-2025
61 companies · $8,896 in 2025
The $8,896 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $305 · 2021: $957 · 2022: $1,666 · 2023: $1,998 · 2024: $7,420 · 2025: $8,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,743 · Food and Beverage: $6,931 · Travel and Lodging: $1,615 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,742.50 |
| Food and Beverage | $6,931.04 |
| Travel and Lodging | $1,614.79 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,706.25 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $3,354.23 | 2023-2024 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $954.04 | 2019-2025 | Opdualag, Opdivo, Augtyro |
| Astrazeneca Pharmaceuticals LP | $910.80 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $752.45 | 2019-2025 | |
| Celgene Corporation | $571.53 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $512.65 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $435.94 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Janssen Biotech, INC. | $371.84 | 2021-2025 | Darzalex, Tecvayli, Balversa |
| Pharmacyclics LLC, An Abbvie Company | $342.50 | 2021-2023 | Imbruvica |
| Eisai INC. | $316.56 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $310.16 | 2021-2025 | |
| Seagen INC. | $298.70 | 2020-2023 | Padcev, Tukysa |
| Dendreon Pharmaceuticals LLC | $287.32 | 2019-2025 | Provenge |
| Genentech USA, INC. | $266.96 | 2019-2025 | Venclexta, Phesgo, Polivy |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $256.93 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Gilead Sciences, INC. | $250.35 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $235.33 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $178.04 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $162.77 | 2019-2025 | Jakafi |
| Abbvie INC. | $160.94 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.94 | 2021-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Genmab U.S., INC. | $130.78 | 2023-2024 | Epkinly, Tivdak |
| Taiho Oncology, INC. | $121.11 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $104.67 | 2024-2025 | |
| Mirati Therapeutics, INC. | $104.06 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $97.75 | 2023-2024 | Fotivda |
| Pharmacosmos Therapeutics INC. | $96.83 | 2024-2025 | Monoferric |
| Sobi, INC | $91.14 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.93 | 2022-2024 | Libtayo |
| Tempus Ai, INC | $83.72 | 2024-2025 | Xt Cdx |
| Medtronic, INC. | $76.74 | 2023 | Osteocool Rf Ablation System |
| Exelixis INC. | $74.31 | 2021-2023 | Cabometyx |
| Array Biopharma INC | $71.76 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Adc Therapeutics America, INC. | $59.67 | 2024 | |
| Genzyme Corporation | $52.60 | 2019-2025 | |
| Beone Medicines USA, INC. | $51.67 | 2025 | Tevimbra, Brukinsa |
| Geron Corporation | $51.31 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $50.52 | 2022-2025 | |
| Emmaus Medical, INC. | $49.67 | 2022 | |
| Stemline Therapeutics INC. | $48.78 | 2023-2024 | Orserdu |
| Amgen INC. | $44.81 | 2019-2023 | Xgeva, Nplate |
| Beigene USA, INC. | $44.75 | 2022-2023 | Brukinsa |
| Menarini Silicon Biosystems, INC. | $43.22 | 2025 | Cellsearch |
| Agios Pharmaceuticals, INC. | $34.69 | 2025 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.12 | 2021-2025 | |
| Morphosys, US INC. | $30.93 | 2023 | Monjuvi |
| Myovant Sciences INC. | $27.97 | 2021-2022 | |
| Emd Serono, INC. | $18.89 | 2024 | |
| Jazz Pharmaceuticals INC. | $18.88 | 2024 | |
| Spectrum Pharmaceuticals INC. | $18.43 | 2024 | Rolvedon |
| Karyopharm Therapeutics INC. | $17.53 | 2025 | Xpovio |
| Kite Pharma, INC. | $17.13 | 2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $16.74 | 2024 | Ultomiris |
| Dova Pharmaceuticals | $15.22 | 2019 | |
| Foundation Medicine, INC. | $14.66 | 2019 | |
| Blueprint Medicines Corporation | $14.56 | 2023 | Ayvakit |
| Legend Biotech USA INC. | $14.36 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $14.18 | 2024 | Qinlock, Tgct |
| Ipsen Biopharmaceuticals, INC | $14.14 | 2022 | |
| Recordati_rare_diseases_inc. | $13.71 | 2025 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.